engineered T-cell combinations with immunotherapy / EOM Pharma, University of Maryland - LARVOL DELTA

A Mathematical Model of TCR-T Cell Therapy for Cervical Cancer. (PubMed, Bull Math Biol) - "Engineered T cell receptor (TCR)-expressing T (TCR-T) cells are intended to drive strong anti-tumor responses upon recognition of the specific cancer antigen, resulting in rapid expansion in the number of TCR-T cells and enhanced cytotoxic functions, causing cancer cell death...We also establish two important factors influencing tumor regression: the reversal of the immunosuppressive TME following depletion of Tregs, and the increased number of effector TCR-T cells with antitumor activity. Using mathematical modeling, we show that certain parameters, such as increasing the cytotoxicity of effector TCR-T cells and modifying the number of TCR-T cells, play important roles in determining outcomes."

Journal • Cervical Cancer • Oncology • Solid Tumor

Immunotherapy in Multiple Myeloma: Boom or Bust? Investigating Oligoclonal Banding and Survival in Multiple Myeloma Patients Receiving Anti CD3-CD28 Co-Stimulated and Engineered Autologous T cells after Autologous Stem Cell Transplant. (IMW 2019) - "... Our data showed that use of engineered T cells did not increase frequency of OCB and was associated with shorter DFS and OS. Study and control groups were well matched based on demographic and clinical characteristics; however, more patients in the study group did not receive maintenance therapy (18.3% vs 10.8 %, p = 0.1). There was no difference in frequency of OCB between the cohorts. Multivariable Cox regression model stratified by cytogenetic risk (n = 153) showed that the study cohort trended towards worse DFS (HR = 1.47, 95% CI [.92, 2.37], p = 0.11) and OS (HR = 1.52, 95% CI [0.83, 2.76], p = 0.17; median OS 8.9 years in controls vs 5.3 years in study cohort)."

Clinical • IO Biomarker